Literature DB >> 16215713

Interaction between simvastatin and metoprolol with respect to cardiac beta-adrenoceptor density, catecholamine levels and perioperative catecholamine requirements in cardiac surgery patients.

A Franka Nette1, Getu Abraham, Fritz Rupert Ungemach, Reinhard Oertel, Wilhelm Kirch, Kirsten Leineweber, Friedrich-Wilhelm Mohr, Stefan Dhein.   

Abstract

UNLABELLED: Beta-blockade is a standard cardiovascular therapy known to induce the up-regulation of beta-adrenoceptor density. Upon ligand-binding, beta-adrenoceptors are normally internalised via the arrestin pathway, and after dissociation they are re-inserted into the membrane. This means that at high catecholamine levels the adrenoceptor density is low and under beta-blockade it is high. The insertion of receptors into the membrane is often dependent on farnesylation processes that can be inhibited by statins. We carried out a prospective, controlled, observational study to determine whether beta-blockade-induced up-regulation of beta-adrenoceptor density is attenuated by statin therapy and whether this would subsequently affect catecholamine consumption during surgery. We obtained pre-operative blood samples and intra-operative biopsies of the right atrial appendage from 39 patients (age: 65+/-5 years; BMI: 28+/-1) undergoing coronary bypass surgery with or without simvastatin (20 mg/day) therapy and with or without concomitant metoprolol therapy (50 mg/day). The atrial tissue was used for radioligand-binding studies with (-)-[125I]-iodocyanopindolol (ICYP) and for assessment of the beta-adrenoceptor subtype distribution following standard protocols. In the blood samples, plasma adrenaline and noradrenaline concentrations were determined using HPLC. In all tissue samples, we found a total beta-adrenoceptor density of 38+/-4 fmol/mg protein in untreated controls; this which was up-regulated to 55+/-5 fmol/mg protein in patients receiving metoprolol. This increase in receptor number was nearly prevented completely by simvastatin therapy (42+/-5 fmol/mg protein). The up-regulation could be attributed to increases in the beta1-adrenoceptor subtype. In contrast, simvastatin alone had no effect on beta-adrenoceptor density. Pre-operative adrenaline levels were slightly reduced in all drug therapy groups (nonsignificant differences), while the levels noradrenaline were not significantly different among the groups. With respect to the perioperative catecholamine requirements, patients on metoprolol needed significantly less dopamine than control patients, while patients undergoing simvastatin/metoprolol therapy needed as much as the controls. The post-operative total catecholamine requirements were not different among the four groups of patients. There were no differences in plasma metoprolol concentration between patients receiving metoprolol alone and those receiving a combination of metoprolol and simvastatin. IN
CONCLUSION: Simvastatin therapy seems to counter-regulate the up-regulation of beta-adrenoceptor density. In the up-regulated state induced by metoprolol therapy, the patients seemed to need less catecholamines during cardiac surgery, which may be due to the higher number of beta-adrenoceptors. Additional simvastatin therapy did not reduce post-operative catecholamine consumption.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16215713     DOI: 10.1007/s00210-005-0005-6

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  51 in total

1.  Increasing sample throughput in pharmacological studies by using dual-column liquid chromatography with tandem mass spectrometry.

Authors:  R Oertel; K Richter; J Fauler; W Kirch
Journal:  J Chromatogr A       Date:  2002-03-01       Impact factor: 4.759

2.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Authors:  P M Ridker; N Rifai; M Clearfield; J R Downs; S E Weis; J S Miles; A M Gotto
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

3.  Diminished responsiveness of Gs-coupled receptors in severely failing human hearts: no difference in dilated versus ischemic cardiomyopathy.

Authors:  O E Brodde; M Vogelsang; A Broede; M Michel-Reher; E Beisenbusch-Schäfer; K Hakim; H R Zerkowski
Journal:  J Cardiovasc Pharmacol       Date:  1998-04       Impact factor: 3.105

4.  G protein gamma subunits with altered prenylation sequences are properly modified when expressed in Sf9 cells.

Authors:  M A Lindorfer; N E Sherman; K A Woodfork; J E Fletcher; D F Hunt; J C Garrison
Journal:  J Biol Chem       Date:  1996-08-02       Impact factor: 5.157

5.  3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1).

Authors:  U Laufs; D Marra; K Node; J K Liao
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

6.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

7.  Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor.

Authors:  G Huhle; C Abletshauser; N Mayer; G Weidinger; J Harenberg; D L Heene
Journal:  Thromb Res       Date:  1999-09-01       Impact factor: 3.944

8.  Ras membrane targeting is essential for glucose signaling but not for viability in yeast.

Authors:  S Bhattacharya; L Chen; J R Broach; S Powers
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

9.  Effects of penbutolol and metoprolol on blood pressure, plasma catecholamines and renin activity in hypertensive patients.

Authors:  B G Hansson; J F Dymling; P Manhem; B Hökfelt
Journal:  Eur Heart J       Date:  1983-07       Impact factor: 29.983

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  6 in total

Review 1.  Cardiovascular function in large to small hibernators: bears to ground squirrels.

Authors:  O Lynne Nelson; Charles T Robbins
Journal:  J Comp Physiol B       Date:  2014-12-27       Impact factor: 2.200

2.  Plasma cortisol response cannot be classically conditioned in a taste-endocrine paradigm in humans.

Authors:  Liubov Petrakova; Karoline Boy; Marisa Kügler; Sven Benson; Harald Engler; Lars Möller; Manfred Schedlowski
Journal:  Psychopharmacology (Berl)       Date:  2017-08-13       Impact factor: 4.530

Review 3.  [Perioperative cardioprotection. Golden standard beta-blockade?].

Authors:  Nils Butte; B W Böttiger; P Teschendorf
Journal:  Anaesthesist       Date:  2007-03       Impact factor: 1.041

4.  Effects of 4-week administration of simvastatin in different doses on heart rate and blood pressure after metoprolol injection in normocholesterolaemic and normotensive rats.

Authors:  Jacek Owczarek; Magdalena Jasińska; Irena Wejman; Urszula Kurczewska; Daria Orszulak-Michalak
Journal:  Arch Med Sci       Date:  2012-02-29       Impact factor: 3.318

5.  Effects of β-Adrenoceptor and Catechol-O-Methyl-Transferase (COMT) Polymorphism on Postoperative Outcome in Cardiac Surgery Patients.

Authors:  Stefan Dhein; Pascal M Dohmen; Matthias Sauer; Julia Tews; Johannes Weickmann; Anne-Kathrin Funkat; Martin Misfeld; Michael A Borger; Friedrich W Mohr
Journal:  Med Sci Monit Basic Res       Date:  2017-05-19

6.  Concomitant administration of simvastatin with ivabradine in contrast to metoprolol intensifies slowing of heart rate in normo- and hypercholesterolemic rats.

Authors:  Jacek Owczarek; Magdalena Jasińska; Jarosław Drożdż; Daria Orszulak-Michalak
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.